Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 255  

 
   Table of Contents      
ORIGINAL ARTICLE
Year : 2017  |  Volume : 16  |  Issue : 2  |  Page : 140-144

Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits


1 Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India
2 Isotope Production and Applications Division, Bhabha Atomic Research Centre, Trombay, Mumbai, Maharashtra, India

Date of Web Publication27-Mar-2017

Correspondence Address:
Venkatesh Rangarajan
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, E. Borges Road, Parel, Mumbai - 400 012, Maharashtra
India
Login to access the Email id


DOI: 10.4103/1450-1147.203072

PMID: 28553181

Rights and Permissions
   Abstract 

Somatostatin receptor positron emission tomography–computed tomography (PET/CT) with 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) peptides have become an indispensable part of disease assessment in patients with neuroendocrine tumors and forms the basis of personalized therapy with peptide receptor-based radionuclide therapy. With growing utilization of PET/CT in developing countries, availability of the indigenous GMP-certified 68Ge/68Ga generators is expected to further promote cost-effective molecular imaging service to the cancer patients. We present our initial clinical experience in 32 patients injected with 68Ga-DOTA-NOC prepared using 68Ga eluted from Bhabha Atomic Research Centre nanoceria-polyacrylonitrile sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC cold kits.

Keywords: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid NOC cold kits, 68Ge/68Ga generator, Bhabha Atomic Research Centre, nanoceria, positron emission tomography-computed tomography


How to cite this article:
Chandra P, Shetye B, Chakravarty R, Mukherjee A, Pandey U, Jha AK, Purandare N, Shah S, Agrawal A, Ram R, Dash A, Rangarajan V. Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits. World J Nucl Med 2017;16:140-4

How to cite this URL:
Chandra P, Shetye B, Chakravarty R, Mukherjee A, Pandey U, Jha AK, Purandare N, Shah S, Agrawal A, Ram R, Dash A, Rangarajan V. Initial clinical experience with 68Ga-DOTA-NOC prepared using 68Ga from nanoceria-polyacrylonitrile composite sorbent-based 68Ge/68Ga generator and freeze-dried DOTA-NOC kits. World J Nucl Med [serial online] 2017 [cited 2019 Dec 7];16:140-4. Available from: http://www.wjnm.org/text.asp?2017/16/2/140/203072


   Introduction Top


Widespread availability of positron emission tomography–computed tomography (PET/CT) along with the development of many radiolabeled 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) conjugated peptides for imaging and therapy of neuroendocrine tumors (NETs) has led to significant progress in the rapidly evolving field of theranostics.[1] In a major step toward providing a cost-effective molecular imaging service to the increasing demands of many nuclear medicine centers in India, Bhabha Atomic Research Centre (BARC), Mumbai, has developed a nanoceria-polyacrylonitrile (CeO2-PAN) composite sorbent-based 68 Ge/68 Ga Generator and single vial freeze-dried cold kits of DOTA-NOC for instantaneous labeling with 68 Ga from the generator without the need for automated systems.[2],[3]

Compared to the other available commercial generators, this novel generator is reported to have consistent 68 Ga yield, minimal metal impurities, and very low 68 Ge breakthrough when long-term elution profiles were studied.[4] Another advantage is that it provides 68 Ga of requisite quality without the need for postelution processing. Hence, such cost-effective, GMP-compliant generator could be easily used in clinical settings in hospital radio-pharmacy like the 99 Mo-99mTc generators.[1],[2],[3]

We present our initial clinical experience in 32 patients injected with 68 Ga-DOTA-NOC prepared using 68 Ga eluted from BARC CeO2-PAN sorbent-based 68 Ge/68 Ga generator and freeze-dried DOTA-NOC cold kits for various clinical indications.


   Materials and Methods Top


Materials

DOTA-NOC was procured from ABX, Germany. Sodium acetate and Suprapure HCl were purchased from Fluka, USA, and MERCK, Darmstadt, Germany, respectively. All reagents were prepared using sterile high-performance liquid chromatography (HPLC) grade water (Merck, India). Sterility test kits were obtained from Himedia Laboratories, India, and Endosafe PTS equipment and cartridges were from Charles River Laboratories Pvt. Ltd., India. ITLC SG paper was from Agilent Technologies, USA, whereas Whatman 3 mm chromatography strips were from Whatman, UK.

Radioactivity measurements were made using a NaI (Tl) counter (ECIL, India). An HPLC system (JASCO, Japan) equipped with a C-18 reversed phase column coupled to an ultraviolet/visible detector and a NaI (Tl) radioactivity detector (Raytest, Germany) was used for characterization of radiolabeled peptides. Alpha 1–2 LD plus freeze dryer was purchased from Martin Christ, GmBH while 0.22 μm membrane filters (33 mm) were from M/s. Millipore Corporation, Bedford, Massachusetts, USA. PET/CT studies were acquired on Philips Medical Systems, Ohio, USA GEMINI TOF 64.

Methods

Development of 68 Ge/68 Ga generator

The CeO2-PAN sorbent was prepared by the decomposition of the cerium oxalate precursor to cerium oxide followed by incorporation in the PAN matrix, as reported earlier.[2] To fabricate a 68 Ge/68 Ga generator, a borosilicate glass column of dimension 7 cm × 0.8 cm (id) with a sintered disk (G2) at the bottom was packed with 0.5 g of the sorbent, in a lead shield. The column matrix was conditioned at pH 3 by passing 100 mL of 0.001 M HCl solution, at a flow rate of ~2 mL/min. The loading solution (100 mL) containing 740 MBq (20 mCi) of 68 Ge maintained at pH ~3 was allowed to percolate into the column at a flow rate of 0.5–1 mL/min. The column was then washed with 200 mL of 0.1 M HCl (pH 1) solution.

Formulation of 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-NOC kits and radiolabeling with 68 Ga

Single vial kits of DOTA-NOC were formulated in 0.5 M sodium acetate, freeze dried, vacuum sealed under sterile conditions and stored at −20°C, as reported elsewhere.[3],[5] Aseptically prepared 0.1 N HCl was provided with the kits for elution of 68 Ga from the generator. Quality control of the kits was carried out by evaluating their sterility and apyrogenicity, as per the guidelines of Indian Pharmacopeia. Radiochemical yield (RCY) and radiochemical purity of 68 Ga-DOTA-NOC were determined by paper chromatography (PC) as per the reported procedure.[3],[5] For preparation of patient dose of 68 Ga-labeled DOTA-NOC,68 GaCl3 from the nanoceria-PAN 68 Ge/68 Ga generator was eluted using 1 mL of sterile 0.1 N HCl directly into DOTA-NOC cold kit vial. Reaction was carried out at 90°C for 10 min. RCY of 68 Ga-DOTA-NOC was estimated by PC.68 Ga-DOTA-NOC was then filtered through 0.22 μ sterile filter, diluted with sterile saline (2 mL), and injected into the patients.

Clinical studies

We retrospectively studied 32 patients from June to July 2013 (age 16–73, mean 52) wherein 68 Ga-DOTA-NOC PET/CT was done as part of their treatment management. After obtaining a scout image, breath hold CT was acquired followed by whole body CT and then PET acquisition. PET acquisition time was 2 min/per bed position. CT parameters for breath-hold CT includes slice thickness 3 mm, pitch 1.08, field of view - 356 mm, voltage - 120 kV with automated mA correction, image matrix - 512 mL × 512. 80 mL of low osmolar nonionic intravenous contrast was administered in all eligible patients at a rate of 1.8 mL/s and scan delay was 50 s. Images were reconstructed iteratively using RAMLA algorithm. Images were viewed on display system having extended brilliance workspace software (EBW) version 4.5.3.40140 (Netherlands), Philips Healthcare. In addition to the PET/CT, all patients underwent 99mTc-hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) whole body planar scan with single photon emission CT (SPECT) acquisition on Infinia, Hawkeye, GE Healthcare, as standard of care. Relative performances of PET and SPECT studies were analyzed. All studies were acquired with prior informed consent from patients.


   Results Top


The generator was able to provide 68 Ga activity (in the form of 68 GaCl3) in consistent yields and acceptable radionuclidic purity (<10 − 4% of 68 Ge breakthrough). Schematic of 68 Ge/68 Ga Generator is depicted in [Figure 1]. DOTA-NOC cold kits each consisting of 50 μg of the peptide conjugate in 0.5 M sodium acetate (13 mg) could be successfully formulated. The formulated kits were found to be of pharmaceutical grade as per sterility tests and BET tests. Greater than 95% radiolabeling yields could be obtained on radiolabeling with 68 Ga, as ascertained by the chromatography techniques. Specifications of DOTA-NOC kit and 68 Ga-DOTA-NOC are given in [Table 1].
Figure 1: Schematic diagram of Bhabha Atomic Research Centre 68Ge-68Ga generator

Click here to view
Table 1: Generator and cold kit performance parameters

Click here to view


Clinical studies

68 Ga-DOTA-NOC PET/CT was positive in 22/32 patients (12 - initial characterization/staging/diagnosis, 10 - restaging) [Figure 2] and [Figure 3]. PET/CT was negative in 10/32 patients (4 - medullary Ca thyroid, 1 - suspected Insulinoma, 3 metastatic NET with MiB index, 1 - Ectopic Cushing's syndrome, 1 - thymoma) [Table 2]a and [Table 2]b. Number of lesions identified on 68 Ga-DOTA-NOC PET/CT was 142 and on the whole body 99mTc-HYNIC-TOC scintigraphy was 85 [Table 3].
Figure 2: 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NOC positron emission tomography–computed tomography of a 54-year-old patient, showing maximum intensity projection (a), transaxial positron emission tomography (b) and fused positron emission tomography–computed tomography (c) showing focal increased tracer uptake in the left glomus jugulare (white arrow)

Click here to view
Figure 3: Case of solitary liver metastasis from an operated case of duodenal neuroendocrine tumor showing fused images of negative 99mTc-hydrazinonicotinyl-Tyr3-octreotide single photon emission computed tomography/computed tomography (a) study and positive 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NOC positron emission tomography–computed tomography (b, white arrow) study

Click here to view
Table 2a: Indications and results of 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NOC positron emission tomography–computed tomography for initial characterization

Click here to view
Table 2b: Indications and results of 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NOC positron emission tomography–computed tomography for follow-up evaluation

Click here to view
Table 3: Comparison of relative performance of 99mTc-hydrazinonicotinyl-Tyr3-octreotide TOC single photon emission computed tomography and 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NOC positron emission tomography–computed tomography for lesions detection

Click here to view



   Discussion Top


Molecular imaging with 68 Ga radiopharmaceuticals is rapidly evolving. Somatostatin receptor (SSTR) targeting 68 Ga-DOTA peptides have been successfully investigated in multiple clinical indications such as neuro-endocrine tumors, para-gangliomas, neuroblastomas, meningiomas, and oncogenic oseteomalacia.[6] Beyond SSTR imaging, promising clinical studies have emerged using 68 Ga with biomolecules such as PSMA, bombesin, and macroaggregated albumin.[7],[8],[9]

The first and foremost important clinical indication for 68 Ga-DOTA peptides have been NETs. NET represents a subset of tumors originating from enterochromaffin cells of the foregut, midgut, or hindgut. Survivor, Epidemiology and End results database has shown rise in the incidence of NET for the past few decades, probably related to the increased detection rate.[10] Prognosis of this disease is highly dependent on stage with 5-year survival in localized disease above 905 and 5-year survival about <30% in patients with distant metastasis.[11] Knowing the tumor biology, its location and extent through imaging has been to improve patient's treatment outcomes.[12] SSTR PET/CT is proven to be diagnostically superior to conventional scinitigraphy and CT and used extensively for staging, restaging and assessing response to treatment in patients with NET.[13]68 Ga-DOTA-NOC PET/CT impacts management of NET patients by modifying treatment in over 50% of referred patients.[14]68 Ga-SSTR-PET/CT forms the basis of selecting patients for PRRT, a new and promising treatment for NET patients. PRRT has shown response rates of 25–30% with comparable progression-free survival and overall survival with other available medical treatments.[15]

The increasing need of 68 Ga-labeled molecules for the above-mentioned oncological and nononcological indications has propelled the development of many GMP-certified 68 Ga-Generators. Despite excellent advances of present-day 68 Ga-radiopharmacy, it is pertinent to point out that majority of the commercially available 68 Ge/68 Ga generators have several shortcomings and are not directly amenable for use in clinical context.[16],[17] To circumvent these limitations, “state-of-the-art” automated modules have been developed over the last few years for postelution processing of 68 Ga and subsequent radiopharmaceutical preparation.[18],[19] However, these automated modules are highly expensive and beyond the reach of most nuclear medicine departments, especially in developing countries. Therefore, we have indigenously developed a 68 Ge/68 Ga generator using CeO2-PAN sorbent which could directly be used for the preparation of radiopharmaceuticals. Recently, Isotope Technologies Garching GmBH has launched a new GMP-certified 68 Ge/68 Ga generator in the clinical market that utilizes pyrogallol-derivatized SiO2 as an adsorbent and is directly amenable for clinical use. A detailed performance evaluation of both these generators was recently carried out by our group, and the performances of these two generators were found to be comparable.[20] Thus, we could ensure that our indigenously developed generator is suitable for clinical use.

To achieve the goal of making 68 Ga as the “work-horse” of PET, just as 99mTc is for SPECT, it is prudent to develop cold kits containing precursors in freeze-dried form for extemporaneous preparation of 68 Ga radiopharmaceuticals. Our group has demonstrated feasibly of preparation of 68 Ga radiopharmaceuticals utilizing cold kits of peptide conjugates.[3],[5] Herein, we report our first clinical experience with 68 Ga-DOTA-NOC prepared using 68 Ga from the indigenous generator and freeze-dried cold kits of DOTA-NOC.68 Ga-DOTA-NOC in consistently high yields could be prepared in 10 min and within 35 min, radiolabeled DOTA-NOC was ready for injection into the patients after quality control analysis. Moreover, availability of cold kits independent of 68 Ga generator provides more control over the reaction parameters compared to automated modules for 68 Ga radiopharmaceutical preparation.

We analyzed the application of 68 Ga-DOTA-NOC imaging for a wide variety of indications, which included pulmonary/gastro-enteropancreatic NETs, paragangliomas, ectopic ACTH syndrome, suspected meningioma, and tumor-induced osteomalacia. PET/CT showed intense uptake in two patients with paraganglioma and two patients with suspected meningioma, supporting the increasing use of PET/CT for these indications. PET/CT was successful in localizing the primary tumor in four patients (1 - tumor induced osteomalacia, 3 - metastatic NET of unknown primary). PET/CT was negative in 10 patients (4 - medullary Ca thyroid, 1 - suspected insulinoma, 3 metastatic NET with high proliferation index, 1 - ectopic Cushing's syndrome, 1 - thymoma). Compared to the standard imaging for NET,99mTc-HYNIC TOC, significantly more number of lesions was identified on 68 Ga-DOTA-NOC PET-CT. However a change of management was noted in only one patient, which could be explained by small number of patients and heterogeneous clinical indications in our study.


   Conclusion Top


The first clinical experience with BARC's CeO2-PAN sorbent-based 68 Ge/68 Ga Generator and freeze-dried DOTA-NOC kits was found to be satisfactory in various clinical indications. Larger studies can be considered, to promote its widespread use as a cost-effective molecular imaging agent for the assessment of NETs.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: Valuable tools for the detection and treatment of cancer. Theranostics 2012;2:481-501.  Back to cited text no. 1
    
2.
Chakravarty R, Shukla R, Ram R, Venkatesh M, Dash A, Tyagi AK. Nanoceria-PAN composite-based advanced sorbent material: A major step forward in the field of clinical-grade 68Ge/68Ga generator. ACS Appl Mater Interfaces 2010;2:2069-75.  Back to cited text no. 2
    
3.
Mukherjee A, Pandey U, Chakravarty R, Sarma HD, Dash A. Development of single vial kits for preparation of (68) Ga-labelled peptides for PET imaging of neuroendocrine tumours. Mol Imaging Biol 2014;16:550-7.  Back to cited text no. 3
    
4.
Chakravarty R, Chakraborty S, Ram R, Dash A, Pillai MR. Long-term evaluation of 'BARC 68Ge/68Ga generator' based on the nanoceria-polyacrylonitrile composite sorbent. Cancer Biother Radiopharm 2013;28:631-7.  Back to cited text no. 4
    
5.
Mukherjee A, Pandey U, Chakravarty R, Sarma HD, Samuel G, Dash A. Single vial kit formulation for preparation of PET radiopharmaceutical:68 Ga-DOTATOC. J Radioanal Nucl Chem 2014;302:1253-8.  Back to cited text no. 5
    
6.
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-16.  Back to cited text no. 6
    
7.
Avanesov M, Karul M, Derlin T. (68) Ga-PSMA as a new tracer for evaluation of prostate cancer: Comparison between PET-CT and PET-MRI in biochemical recurrence. Radiologe 2015;55:89-91.  Back to cited text no. 7
    
8.
Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with 18F-FDG. J Nucl Med 2007;48:1245-50.  Back to cited text no. 8
    
9.
Siva S, Devereux T, Ball DL, MacManus MP, Hardcastle N, Kron T, et al. Ga-68 MAA perfusion 4D-PET/CT scanning allows for functional lung avoidance using conformal radiation therapy planning. Technol Cancer Res Treat 2016;15:114-21.  Back to cited text no. 9
    
10.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.  Back to cited text no. 10
    
11.
Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004;80 Suppl 1:3-7.  Back to cited text no. 11
    
12.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.  Back to cited text no. 12
    
13.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18.  Back to cited text no. 13
    
14.
Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669-73.  Back to cited text no. 14
    
15.
van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 2015;172:R1-8.  Back to cited text no. 15
    
16.
Roesch F, Riss PJ. The renaissance of the 68 Ge/68 Ga radionuclide generator initiates new developments in 68 Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010;10:1633-68.  Back to cited text no. 16
    
17.
Rösch F. (68) Ge/(68) Ga generators: Past, present, and future. Recent Results Cancer Res 2013;194:3-16.  Back to cited text no. 17
    
18.
Velikyan I. Prospective of 68 Ga-radiopharmaceutical development. Theranostics 2013;4:47-80.  Back to cited text no. 18
    
19.
Boschi S, Malizia C, Lodi F. Overview and perspectives on automation strategies in (68) Ga radiopharmaceutical preparations. Recent Results Cancer Res 2013;194:17-31.  Back to cited text no. 19
    
20.
Chakravarty R, Chakraborty S, Ram R, Vatsa R, Bhusari P, Shukla J, et al. Detailed evaluation of different (68) Ge/(68) Ga generators: An attempt toward achieving efficient (68) Ga radiopharmacy. J Labelled Comp Radiopharm 2016;59:87-94.  Back to cited text no. 20
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]


This article has been cited by
1 Clinical experience with indigenous kit-based preparation of 68 Ga-DOTATOC using commercial 68 Ge/ 68 Ga generator
Usha Pandey,Aruna Korde,Archana Mukherjee,Ajit Shinto,K.K. Kamaleswaran,Raghi P. Jose,Naresh Gamre,Ashutosh Dash
Applied Radiation and Isotopes. 2018; 136: 59
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1264    
    Printed16    
    Emailed0    
    PDF Downloaded145    
    Comments [Add]    
    Cited by others 1    

Recommend this journal